Skip to content

Nuvalent, Inc. NUVL Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Pfizer logo
PfizerPFE
Summit Therapeutics logo
Summit TherapeuticsSMMT
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Incyte logo
IncyteINCY
ALN
Alnylam PharmaceuticalsALNY
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s software and technology licenses, net?
Nuvalent, Inc. (NUVL) reported software and technology licenses, net of $23.21M in Q1 2026.
How has Nuvalent, Inc.'s software and technology licenses, net changed year-over-year?
Nuvalent, Inc.'s software and technology licenses, net increased by 20.6% year-over-year, from $19.25M to $23.21M.
What is the long-term trend for Nuvalent, Inc.'s software and technology licenses, net?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s software and technology licenses, net has grown at a 58.7% compound annual growth rate (CAGR), from $3.2M to $20.28M.